Floatz logo

Acalabrutinib

Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)

Acerta Pharma BVSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL) cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Mayo Clinic
Phase 2/3BB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 2/3BB
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3BB
Inno-206
National Cancer Institute (NCI)
Phase 2/3BB

View all 20 →

Same molecule, other indications

Acalabrutinib is also rated in:

B-cell chronic lymphocytic leukemiaDormant
BBB
Indicative ·
75 / 100
View asset →
Grade 3a Follicular LymphomaDormant
BB
Indicative ·
70 / 100
View asset →
follicular lymphomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →